vs
Side-by-side financial comparison of FONAR CORP (FONR) and Outset Medical, Inc. (OM). Click either name above to swap in a different company.
Outset Medical, Inc. is the larger business by last-quarter revenue ($28.9M vs $25.5M, roughly 1.1× FONAR CORP). FONAR CORP runs the higher net margin — 8.0% vs -67.5%, a 75.6% gap on every dollar of revenue. On growth, FONAR CORP posted the faster year-over-year revenue change (2.4% vs -2.0%). FONAR CORP produced more free cash flow last quarter ($-227.0K vs $-9.7M). Over the past eight quarters, Outset Medical, Inc.'s revenue compounded faster (1.2% CAGR vs -0.3%).
FONAR Corp is a specialized medical technology firm that designs, manufactures, and distributes innovative MRI systems including upright and open models. It primarily serves U.S. hospitals, diagnostic imaging centers, and healthcare providers, delivering high-precision scanning solutions for clinical diagnostic use.
Outset Medical, Inc. is a medical technology company focused on developing and commercializing innovative dialysis solutions for patients living with kidney disease. Its flagship Tablo Hemodialysis System supports use in acute care facilities, outpatient clinics, and home settings, serving healthcare providers and patients across the U.S. and select international markets.
FONR vs OM — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.5M | $28.9M |
| Net Profit | $2.1M | $-19.5M |
| Gross Margin | — | 42.4% |
| Operating Margin | 13.5% | -61.1% |
| Net Margin | 8.0% | -67.5% |
| Revenue YoY | 2.4% | -2.0% |
| Net Profit YoY | 4.7% | 24.0% |
| EPS (diluted) | — | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.5M | $28.9M | ||
| Q3 25 | $26.0M | $29.4M | ||
| Q2 25 | $27.3M | $31.4M | ||
| Q1 25 | $27.2M | $29.8M | ||
| Q4 24 | $24.9M | $29.5M | ||
| Q3 24 | $25.0M | $28.7M | ||
| Q2 24 | $25.9M | $27.4M | ||
| Q1 24 | $25.7M | $28.2M |
| Q4 25 | $2.1M | $-19.5M | ||
| Q3 25 | $2.3M | $-17.8M | ||
| Q2 25 | $729.3K | $-18.5M | ||
| Q1 25 | $2.5M | $-25.8M | ||
| Q4 24 | $2.0M | $-25.6M | ||
| Q3 24 | $3.1M | $-27.9M | ||
| Q2 24 | $830.4K | $-34.5M | ||
| Q1 24 | $1.9M | $-39.9M |
| Q4 25 | — | 42.4% | ||
| Q3 25 | — | 39.4% | ||
| Q2 25 | — | 37.8% | ||
| Q1 25 | — | 37.2% | ||
| Q4 24 | — | 36.5% | ||
| Q3 24 | — | 34.3% | ||
| Q2 24 | — | 35.7% | ||
| Q1 24 | — | 29.2% |
| Q4 25 | 13.5% | -61.1% | ||
| Q3 25 | 14.1% | -53.7% | ||
| Q2 25 | 5.3% | -53.7% | ||
| Q1 25 | 15.2% | -55.1% | ||
| Q4 24 | 11.9% | -74.2% | ||
| Q3 24 | 21.0% | -83.2% | ||
| Q2 24 | 7.4% | -112.3% | ||
| Q1 24 | 16.8% | -131.0% |
| Q4 25 | 8.0% | -67.5% | ||
| Q3 25 | 8.7% | -60.6% | ||
| Q2 25 | 2.7% | -59.0% | ||
| Q1 25 | 9.2% | -86.7% | ||
| Q4 24 | 7.9% | -87.0% | ||
| Q3 24 | 12.6% | -97.5% | ||
| Q2 24 | 3.2% | -125.8% | ||
| Q1 24 | 7.3% | -141.8% |
| Q4 25 | — | $0.33 | ||
| Q3 25 | — | $-1.00 | ||
| Q2 25 | — | $-1.04 | ||
| Q1 25 | — | $-3.66 | ||
| Q4 24 | — | $-7.21 | ||
| Q3 24 | — | $-8.02 | ||
| Q2 24 | — | $-9.96 | ||
| Q1 24 | — | $-11.77 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $121.0K | $168.9M |
| Total DebtLower is stronger | — | $96.2M |
| Stockholders' EquityBook value | $176.9M | $127.0M |
| Total Assets | $217.2M | $264.5M |
| Debt / EquityLower = less leverage | — | 0.76× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $121.0K | $168.9M | ||
| Q3 25 | $122.0K | $178.6M | ||
| Q2 25 | $56.5M | $184.1M | ||
| Q1 25 | $123.0K | $189.0M | ||
| Q4 24 | $121.0K | $158.7M | ||
| Q3 24 | $136.0K | $175.6M | ||
| Q2 24 | $56.5M | $194.8M | ||
| Q1 24 | $134.0K | $226.9M |
| Q4 25 | — | $96.2M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $197.4M | ||
| Q3 24 | — | — | ||
| Q2 24 | $66.9K | — | ||
| Q1 24 | — | — |
| Q4 25 | $176.9M | $127.0M | ||
| Q3 25 | $174.9M | $142.4M | ||
| Q2 25 | $172.6M | $154.8M | ||
| Q1 25 | $171.9M | $169.9M | ||
| Q4 24 | $169.8M | $26.8M | ||
| Q3 24 | $168.7M | $47.8M | ||
| Q2 24 | $166.0M | $68.6M | ||
| Q1 24 | $165.8M | $93.2M |
| Q4 25 | $217.2M | $264.5M | ||
| Q3 25 | $218.4M | $277.3M | ||
| Q2 25 | $216.9M | $288.8M | ||
| Q1 25 | $214.9M | $301.2M | ||
| Q4 24 | $208.0M | $275.8M | ||
| Q3 24 | $212.3M | $292.9M | ||
| Q2 24 | $214.2M | $314.5M | ||
| Q1 24 | $209.6M | $346.2M |
| Q4 25 | — | 0.76× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.36× | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $171.0K | $-9.5M |
| Free Cash FlowOCF − Capex | $-227.0K | $-9.7M |
| FCF MarginFCF / Revenue | -0.9% | -33.7% |
| Capex IntensityCapex / Revenue | 1.6% | 0.8% |
| Cash ConversionOCF / Net Profit | 0.08× | — |
| TTM Free Cash FlowTrailing 4 quarters | $5.7M | $-47.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $171.0K | $-9.5M | ||
| Q3 25 | $1.7M | $-6.3M | ||
| Q2 25 | $4.2M | $-4.8M | ||
| Q1 25 | $3.1M | $-25.7M | ||
| Q4 24 | $2.2M | $-16.5M | ||
| Q3 24 | $1.7M | $-20.6M | ||
| Q2 24 | $4.6M | $-33.3M | ||
| Q1 24 | $2.8M | $-45.9M |
| Q4 25 | $-227.0K | $-9.7M | ||
| Q3 25 | $-177.0K | $-6.5M | ||
| Q2 25 | $3.6M | $-5.1M | ||
| Q1 25 | $2.6M | $-25.8M | ||
| Q4 24 | $1.5M | $-16.5M | ||
| Q3 24 | $-148.0K | $-21.0M | ||
| Q2 24 | $4.2M | $-33.5M | ||
| Q1 24 | $2.6M | $-46.3M |
| Q4 25 | -0.9% | -33.7% | ||
| Q3 25 | -0.7% | -22.0% | ||
| Q2 25 | 13.1% | -16.3% | ||
| Q1 25 | 9.4% | -86.7% | ||
| Q4 24 | 6.0% | -56.1% | ||
| Q3 24 | -0.6% | -73.1% | ||
| Q2 24 | 16.1% | -122.2% | ||
| Q1 24 | 10.2% | -164.3% |
| Q4 25 | 1.6% | 0.8% | ||
| Q3 25 | 7.2% | 0.5% | ||
| Q2 25 | 2.4% | 0.9% | ||
| Q1 25 | 2.2% | 0.4% | ||
| Q4 24 | 3.0% | 0.1% | ||
| Q3 24 | 7.2% | 1.4% | ||
| Q2 24 | 1.6% | 0.4% | ||
| Q1 24 | 0.7% | 1.3% |
| Q4 25 | 0.08× | — | ||
| Q3 25 | 0.75× | — | ||
| Q2 25 | 5.79× | — | ||
| Q1 25 | 1.26× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 0.53× | — | ||
| Q2 24 | 5.54× | — | ||
| Q1 24 | 1.50× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FONR
| Managementof Diagnostic Imaging Centers | $23.2M | 91% |
| Manufacturingand Servicingof Medical Equipment | $2.4M | 9% |
OM
| Consumables Product | $13.5M | 47% |
| Service And Other Revenue | $9.0M | 31% |
| Consoles Product | $6.4M | 22% |
